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Abstract The long-lasting inadequacy of existing treatments
for prostate cancer has led to increasing efforts for developing
novel therapies for this disease. MicroRNAs (miRNAs) are
believed to have considerable therapeutic potential due to their
role in regulating gene expression and cellular pathways.
Identifying miRNAs that efficiently target genes and path-
ways is a key step in using these molecules for therapeutic
purposes. Moreover, computational methods have been de-
vised to help identify candidate miRNAs for each
gene/pathway. MAPK and JAK/STAT pathways are known
to have essential roles in cell proliferation and neoplastic
transformation in different cancers including prostate cancer.
Herein, we tried to identify miRNAs that target these path-
ways in the context of prostate cancer as therapeutic mole-
cules. Genes involved in these pathways were analyzed with
various algorithms to identify potentially targeting miRNAs.
miR-23a and miR-23b were then selected as the best potential
candidates that target a higher number of genes in these path-
ways with greater predictive scores. We then analyzed the
expression of candidate miRNAs in LNCAP and PC3 cell
lines as well as prostate cancer clinical samples. miR-23a
and miR-23b showed a significant downregulation in cell line
and tissue samples, a finding which is consistent with
overactivation of these pathways in prostate cancer. In addi-
tion, we overexpressed miR-23a and miR-23b in LNCAP and
PC3 cell lines, and these two miRNAs decreased IL-6R
expression which has a critical role in these pathways.
These results suggest the probability of utilizing miR-
23a and miR-23b as therapeutic targets for the treatment
of prostate cancer.
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Introduction
Prostate cancer is the second most common cancer and fifth
cause of cancer death worldwide with an estimated 1,111,689
newly diagnosed cases and 307,471 deaths in 2012 [1]. Con-
sidering the global changes in the aging of the populations, it
is estimated that the numbers will rise to 1,700,000 new cases
and 499,000 deaths by 2030 [2]. Present therapies for prostate
cancer have limited efficacy, and developing new therapeutic
strategies and drugs for controlling prostate cancer is an active
area of research [3].
MicroRNAs (miRNAs) are a class of small endogenous
noncoding RNAs that play a crucial role in regulating gene
expression in different cells and organisms [4]. Each miRNA
can regulate a large number of genes, likely around several
hundred genes in case of mammalian cells [5]. Indeed, this
capability of miRNAs makes these molecules potent regula-
tors of cellular processes, particularly when transcripts belong
to the same pathway. This feature has brought miRNAs to the
spotlight of molecular research for treatment of the human
diseases [6]. Several miRNA-based therapeutics is currently
under investigation and promising developments have been
made in the context of infectious diseases as well as cancers.
SPC3649, a miR-122 antagonist, which is designed to block
the reproduction of HCV in hepatocytes, is presently under-
going a phase 2 clinical trial [7]. For cancer treatment, let-7
and miR-34 are being actively investigated as they show effi-
cient in vitro and in vivo inhibition of cancer cells in culture
and mouse cancer models, respectively [8]. Currently, let-7 is
in preclinical development and miR-34, which displays anti-
neoplastic activity in mouse cancer models including melano-
ma, lymphoma, lung, prostate, and pancreatic cancer, is un-
dergoing phase 1 clinical trial in patients with liver cancer [9].
Identifying the appropriate miRNAs that target desired
pathways and genes is one of the major challenges in using
miRNAs as therapeutic agents [10]. Computational ap-
proaches are useful tools for the prediction of miRNAs that
are more likely to target selected genes or signaling pathways.
Nonetheless, these methods which work based on sequence
complementarity between the miRNA and 3′UTR of messen-
ger RNAs (mRNAs) usually generate a large number of pre-
dicted miRNA-mRNA interactions for each transcript. Sever-
al prediction algorithms have been developed including
TargetScan, miRanda, PicTar, DIANA-microT, and RNA22
[11]. Furthermore, there are some databases, such as TarBase
V 6.0, that present the experimentally validated interactions
between miRNAs and mRNAs [12]. A frequently used
strategy for target prediction is to combine the results of dif-
ferent prediction algorithms to find miRNA-mRNA interac-
tions which are predicted by multiple algorithms and exhibit a
greater combined score [13].
In order to find miRNAs that target prostate cancer, first,
we should select strategic pathways that have a critical role in
pathogenesis and progression of the disease. MAPK and JAK/
STAT are two important pathways that are involved in tumor-
igenesis of prostate cancer [14]. The MAPK pathway exerts
key roles in cell proliferation, gene expression, and differen-
tiation in different cells. It has been reported that the MAPK
pathway has also a major role in tumor growth and metastasis
in prostate cancer [15, 16], and its inhibition prevents prostate
cancer cell growth [17, 18]. The JAK/STAT pathway is anoth-
er key signaling cascade involved in physiological processes
such as cell differentiation, growth, and apoptosis [19]. This
pathway is upregulated in a wide range of cancers including
prostate cancer [20]. Moreover, previous studies have indicat-
ed that blocking this pathway suppresses prostate cancer cell
proliferation and promotes apoptosis of neoplastic cells [21,
22]. The essential roles of these pathways in the prostate can-
cer initiation and progression have made them excellent can-
didates to be investigated in the context of this disease [14]. In
this study, using a combination of computational and experi-
mental approaches, we have tried to identify miRNAs that can
efficiently downregulate these pathways through multi-
targeting of the pathway genes. We report that miR-23a and
miR-23b might be excellent miRNA species for diminishing
the activity of these disease-related pathways.
Materials and methods
Bioinformatics studies
We prepared a list of the genes of MAPK and JAK/STAT
pathways which their activation enhanced but not inhibited
the activity of these pathways. In preparation of this list, we
attempted to consider the key genes that had been reported as
potential drug targets in prior studies concerning prostate can-
cer [14]. The final list included MAP2K1, MAP3K1,
MAP3K12, MAP3K3, MAP3K5, MAP3K7IP2, MAP3K8,
PDGFA, PDGFRA, FAS, FGF1, FGF10, FGF12, FGF3,
FGFR3, HRAS, MEK1, MEK2, BRAF, and RAF1 from the
MAPK pathway and JAK1, JAK2, JAK3, STAT3, IL6R, IL6,
BRCA1, AR, PIK3R3, AKT, and mTOR from the JAK/STAT
pathway. We then analyzed these genes using validated target
databases (i.e., TarBase 6) as well as several target prediction
algorithms, such as DIANA-microT, miRanda, miRDB,
miRWalk, RNAhybrid, PICTAR5, RNA22, and TargetScan.
In addition, the list of the genes was analyzed in the
miRNApath database [23].
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Pathway analysis
DIANAmirPath v.2.0 was used to analyze the target genes for
candidate miRNAs from MAPK and JAK/STAT pathways
[24]. In this database, it is possible to analyze the miRNAs
with a miRNA target prediction algorithm (DIANA-microT-
CDS) or the experimentally validated miRNA targets (DI-
ANA-TarBase v6.0). These predicted and validated interac-
tions for different miRNAs can be combined and presented
graphically for each pathway. For pathway analysis, the se-
lected miRNAs were subjected to both DIANA-microT-CDS
and DIANA-TarBase v6.0 algorithms.
Expression analysis
For the expression analysis, we used the mimiRNA database
to investigate the expression of candidate miRNAs in prostate
tissue and prostate cancer cell lines, LNCAP and PC3 [25].
Prostate cancer cell line preparation
LNCAP and PC3 prostate cancer cell lines were obtained
from the National Cell Bank of Iran (Pasteur Institute of Iran,
Iran). These cell lines were cultured in Dulbecco’s Modified
Eagle Medium (DMEM) (Gibco, USA) containing 10 % fetal
bovine serum (FBS) (Gibco, USA) and antibiotics from Sig-
ma-Aldrich, Germany. After proliferation and reaching 80 %
confluence, cells were trypsinized and washed with DMEM.
Human sample preparation
Human samples were obtained from 16 patients in early stages of
prostate cancer who had undergone radical prostatectomy at Teh-
ran hospitals. All the samples confirmed by pathology tests and
except three patients (samples 6, 13, and 14) who were in the T3
stage, the rest of the patients were in T2 stage. Fourteen patients
had a Gleason score of 7 and the other patients had a Gleason
score of 6 (samples 4 and 8). In addition, ten benign prostatic
hyperplasia (BPH) samples were obtained from patients that
were referred to Tehran hospitals in 2012. Written informed con-
sent was taken from all of the patients. The ethical committee of
the hospitals approved this study by project no. 1544.
Designing stem-loop, primers, and probe for miRNAs
and primers for IL6R
The sequences of the selected miRNAs were obtained from
miRBase (http://www.mirbase.org), and the sequence of IL6R
gene was taken from NCBI Gene (http://www.ncbi.nlm.nih.
gov/gene). The stem-loops, primers, and probes were
designed based on the work from Mohammadi-Yeganeh
et al. [26, 27]. The primers were designed using AlleleID 6
(PREMIER Biosoft International, USA), and the specificity of
each primer was determined via NCBI BLAST (www.ncbi.
nlm.nih.gov/BLAST). All the stem-loops, primers, and probes
were synthesized by Macrogen (Seoul, Korea). Sequences of
primers and probe are shown in Table 1.
miR-23a and miR-23b plasmid construction
DNA was extracted from human blood samples using
QIAamp DNA Mini Kit (Qiagen, Germany) according to the
manufacturer’s instruction. For amplification of miR-23a and
miR-23b, PCR was done using forward and reverse primers
containing Xho1 and Mlu1 restriction sites (Table 1), respec-
tively. This fragment was cloned into the lentiviral vector
pLEX-JRed, which its turbo GFP were extracted by Xho1
enzyme (Open Biosystems, USA) (Fig. 1).
Lentivirus packaging and transduction
Viral packaging cell line HEK 293T cells, were cultured in
DMEM (Gibco, USA) containing 10 % FBS (Gibco, USA)
and antibiotics (Sigma-Aldrich, Germany). Lentivirus pack-
aging was performed using the standard calcium phosphate
method for miR-23a-pLEX-Jred and miR-23b-pLEX-Jred
constructs and intact pLEX-Jred as control. After the transfec-
tion step, supernatants were gathered and used for transducing
cell lines. Media containing lentiviruses were replaced by
fresh medium after 8 h. Two days after transduction, trans-
duced cell lines were treated with 2 μg/ml puromycin for
2 days. The percentage of transduced cells was analyzed under
fluorescent microscope.
mRNA and miRNA extraction
mRNA and miRNA extraction was performed using a modi-
fied RNX-Plus RNA extraction kit (SinaClon, Iran). In short,
2–3×106 of prostate cancer cells from LNCAP and PC3 cell
lines were suspended in 1 ml RNX-Plus. For clinical samples,
100 mg of each sample was homogenized in 1 ml RNX-Plus
using TissueLyser LT (Qiagen, Germany). After 5 min incu-
bation at room temperature, 250 μl chloroform (Merck, Ger-
many) was added to each tube and the tubes were shaken
vigorously. The tubes were then centrifuged by MIKRO 200
R (Hettich, Germany) for 25 min at 12,000g at 4 °C. The
upper phase was transferred to a new tube and an equal vol-
ume of 99% ethanol (Merck, Germany) was added. The tubes
were kept at −20 °C overnight and subsequently centrifuged
for 45 min at 12,000g at 4 °C. The supernatant was then
removed and 1 ml of 70 % ethanol was added. The tubes were
centrifuged for 20 min at 12,000g at 4 °C. The supernatant
was discarded and the RNA pellets were dried at room tem-
perature. The quality and purity of the RNAwas analyzed by
BioPhotometer (Eppendorf, Germany). The RNA samples
were stored at −80 °C until further use.
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Reverse transcription
All the RNA samples were reverse transcribed using
RevertAid Reverse Transcriptase (Thermo Fisher Scientific,
USA). For each tube, 1.5 μl of stem-loop RT primer (50 nM)
for miRNA or 1.5 μl of random hexamer primer (100 nM) for
mRNAwas added to 2 μl of the extracted RNA containing 2–
5μg RNA and 6.5μl distilled water. The tubes were incubated
in a peqSTAR Thermocycler (PEQLAB Biotechnologie
GmbH, Germany) at 75 °C for 5 min. Then, 3 μl of 5× RT
Buffer, 1.5 μl of dNTPMix (10 mM), and 0.5 μl of RevertAid
Reverse Transcriptase were added to each tube. The reverse
transcription was performed by the following setting; 25 °C
for 15 min, 37 °C for 15 min, 42 °C for 45 min, and 70 °C for
10 min for heat inactivation of polymerase.
Real-time PCR
Real-time PCR test for miRNAs was carried out in 10-μl
reactions which consisted of 5 μl of QuantiTect Probe PCR
Kit (Qiagen, Hilden, Germany), 0.2 μM of each primer,
0.1 μM of the probe, 2 μl of complementary DNA (cDNA),
and 1.6 μl of distilled water. Real-time PCR for mRNAs was
done in 13-μl reactions which consisted of 6.5 μl of SYBR®
Premix Ex Taq™ Kit (Takara, Japan), 0.2 μM of each primer,
2 μl of cDNA, and 3.5 μl of distilled water. Amplification was
performed according to the manufacturer’s instructions using
a Rotor-Gene 6000 machine (Corbett Life Science, Australia).
SNORD47 (U47) gene was used as the internal control for
miRNAs and GAPDH gene was used as the internal control
for mRNA. All the reactions were performed in triplicate with
positive, negative, no RT, and no-template controls included.
Data were analyzed with ΔΔCt method.
Statistical analysis
The gene expression analyses were done using Relative Ex-
pression Software Tool (REST 2009, Qiagen, Germany). p-
values less than 0.05 were statistically considered significant.
Results
Bioinformatics analyses
Involved genes in MAPK and JAK/STAT pathways were an-
alyzed with multiple miRNA-target prediction algorithms.
Fig. 1 Vector map of pLEX-
JRed
Table 1 miRNA RT stem-loops, primers and probe and expression and cloning primers
miRNA Forward primer RT stem-loop primer
hsa-miR-23a ATCACATTGCCAGGGATTT GGTCGTATGCAAAGCAGGGTCCGAGGTATC
CATCGCACGCATCGCACTGCATACGACCGGAAAT
hsa-miR-23b ATCACATTGCCAGGGATTA GGTCGTATGCAAAGCAGGGTCCGAGGTATC
CATCGCACGCATCGCACTGCATACGACCGGTAAT
Gene Forward primer Reverse primer
IL-6R TGAGGAAGTTTCAGAACAGTC GACGCACATGGACACTATG
miR-23a CCGCTCGAGTTGATCAAAGGAAGCATCTGG CGACGCGTAGCCACTGTGAACACGAC
miR-23b CCGCTCGAGATATACCTCTAGGATGCCAAC CGACGCGTTCACCAATCAGCTAAGCTC
Universal TaqMan probe: FAM 5′TCCATCGCACGCATCGCACT 3′BHQ-1; universal reverse primer: GAGCAGGGTCCGAGGT; the part of the
sequences in italic is restriction site Xho1 and Mlu1, respectively
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The results of the prediction algorithms (DIANA-microT,
miRanda, miRDB, miRWalk, RNAhybrid, PICTAR5,
RNA22, and TargetScan) and the experimentally validated
targets database (TarBase 6) led us to consider miR-23a and
miR-23b as the best candidates. These miRNAs target the
highest number of the genes in our list with the highest pre-
diction scores. The results of the analysis for each gene by
different algorithms are shown in Table 2. In addition, based
on miRNApath results, miR-23a and miR-23b were the top
miRNAs targeting the highest number of the genes.
Pathway analysis
The target genes of miR-23a-3p and miR-23b-3p are highlight-
ed in MAPK and JAK/STAT pathway diagrams obtained from
DIANA-miRPath database (Fig. 2a, b). In each pathway, sev-
eral genes were targeted by miR-23a and miR-23b.
Expression analysis
In order to have an initial insight about the expression of
miR23a/b in prostate cancer, we first explored previously mea-
sured miRNA levels as submitted to the mimiRNA database.
To this end, we selected twowell-established cell lines PC3 and
LNCAP which are known to have high and low levels of met-
astatic potentials. Searching the database for the transcriptomic
data for these cell lines showed lower levels of miR23a/b in all
two cell lines than normal prostate tissue (Fig. 2c).
Confirmation of the construct and transduction
Recombinant vectors containing mir-23a and mir-23b were se-
quenced, and results showed that the inserted sequences were
error free. LNCAP and PC3 prostate cancer cell lines were trans-
duced with lentiviruses, and fluorescent microscope showed
more than 90 % of prostate cancer cell lines were transducted.
In addition, the overexpression of mir-23a andmir-23b in LNCA
P and PC3was confirmed using real-time PCRwith fold changes
from 2.5 to 23 in different cell lines. An empty pLEX-Jred vector
was used to control cell transduction rate.
miRNA extraction, reverse transcription, and real-time PCR
To gain further information about the role of miR-23a and miR-
23b in the context of prostate cancer, we examined the
Table 2 The result of different algorithms that predict miR-23a and miR-23b target list of genes
Gene TarBase DIANAmT miRanda miRDB miRWalk RNAhybrid PICTAR5 RNA22 TargetScan Sum
MAPK pathway genes
FAS + + + + + + + 7
MAP3K5 + + + + + + + 7
MAP3K1 + + + + + + 6
MAP3K3 + + + + + + 6
MAP3K12 + + + + + 5
MAP3K8 + + + + + 5
PDGFA + + + + + 5
MAP2K1 + + + + 4
FGFR3 + + + 3
MAP3K7IP2 + + + 3
FGF1 + + 2
FGF12 + + 2
PDGFRA + + 2
BRAF + 1
JAK/STAT pathway genes
IL6R + + + + + + + + 7
PIK3R3 + + + + + 5
JAK1 + + + + 4
BRCA1 + + + 3
IL6 + + + 3
JAK2 + + + 3
MTOR + + 2
STAT3 + + 2
AKT1 + 1
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Fig. 2 The target genes of miR-23a-3p and miR-23b-3p in pathways and
their expression in different cell lines. a genes targeted by miR-23a and
miR-23b are highlighted inMAPK pathway. b JAK/STAT pathway. Both
obtained from the DIANA mirPath database. c Expression of miR-23a
and miR-23b in the prostate and different prostate cancer cell lines that
took from the mimiRNA database
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expression of the mature forms of these two miRNAs in the
abovementioned prostate cancer-derived cell lines. When com-
pared with BPH samples, the expression levels of both miR-23a
and miR-23b were substantially reduced in LNCAP and PC3
cancer cell lines (p value <0.001) (Fig. 3a, b). We then analyzed
the expression of miR-23a and miR-23b in surgically removed
tissues from prostate cancer cases, as described in the “Materials
and methods” section. Real-time PCR analyses of clinical sam-
ples also revealed significant downregulation of both miR-23a
and miR-23b compared with BPH samples (Fig. 3c). Overall,
these findings support a potential role for miR23a/b in
neoplastically transformed prostate epithelial cells. In the next
step, we analyzed the expression of miR-23a and IL-6R in mir-
23a-transduced LNCAP and PC3 cell lines (Fig. 4a). Moreover,
we evaluatedmiR-23b and IL-6R inmir-23b-transduced LNCA
P and PC3 cell lines (Fig. 4b). Finally, the results of cell line
models were complemented with the gene expression data of
miR-23a, miR-23b, and IL-6R in all clinical samples totally
(Fig. 4c). The expression of miR-23a, miR-23b, and IL-6R in
each sample is displayed in Fig. 5.
Fig. 3 miR-23a and miR-23b expression in prostate cancer cell lines and
clinical samples. Expression in a LNCAP, b PC3, and c clinical samples.
All the samples normalized with BPH samples. P values less than 0.05,
0.01, and 0.001 are marked with an asterisk (*), two asterisks (**), and
three asterisks (***), respectively
Fig. 4 miR-23a, miR-23b, and IL-6R expression in miR-transduced
prostate cancer cell lines and clinical samples. a Expression of miR-23a
and IL-6R in mir-23a-transduced LNCAP and expression ofmiR-23b and
IL-6R in mir-23b-transduced LNCAP. b Expression of miR-23a and IL-
6R in mir-23a-transduced PC3 and expression of miR-23b and IL-6R in
mir-23b-transduced PC3 and c expression of miR-23a, miR-23b, and IL-
6R in clinical samples. All the samples normalized with BPH samples. P
values less than 0.05, 0.01, and 0.001 are marked with an asterisk (*), two
asterisks (**), and three asterisks (***), respectively
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Discussion
According to International Agency for Research on Cancer
(IARC) in 2012, 15 % of the new cancer cases and 6.6 % of
the cancer deaths among men worldwide are related to pros-
tate cancer [1]. Indeed, the high prevalence rate of this cancer
together with the low efficacy of the current treatments neces-
sitates the development of novel therapies which can reduce
the mortality rate of the disease [3]. miRNAs play critical roles
in posttranscriptional regulation of gene expression and have
recently received considerable attention for therapeutic use
[8]. The distinctive ability of miRNAs to control multiple
genes and pathways simultaneously makes them plausible
candidates to be investigated for therapeutic purposes in the
context of cancer. Some reports indicate that miRNA-
mimicking sequences can efficiently prevent tumor growth
in vitro and in vivo [28]. Liu et al. showed that miR-34a can
inhibit prostate cancer stem cell proliferation and subsequent
spread and metastasis in a mouse model of the disease [29].
Interestingly, miR-34, which could be labeled as the first an-
ticancer therapeutic miRNA, is currently undergoing a phase 1
clinical trials for liver cancer. Several other miRNAs are also
in preclinical development phase [9].
Identification of miRNAs which can target specific tran-
scripts is a challenging step in developing miRNA-based
drugs, and computational algorithms have proven to be valu-
able in this context [11]. In a study conducted by Hen et al.,
computational analysis of pathways associated with pancreat-
ic cancer indicated that miR-548d targeted several nodes of
the pathogenesis network. Overexpression of this miRNA in
pancreatic cancer cells led to cell cycle arrest and increased
apoptosis [10]. In the current study, we selected several genes
from MAPK and JAK/STAT pathways and analyzed each
gene by different algorithms. Finally, miR-23a and miR-23b
were selected as they had been previously predicted to target
various elements in the pathways.
Our results demonstrated that the expression of miR-23a
and miR-23b in two different prostate cancer cell lines were
substantially lower compared with BPH. These multiple pros-
tate cancer cell lines have been derived from different stages
of the disease and have distinctive characteristics. For in-
stance, PC3 cells are extremely tumorigenic and metastatic,
while LNCAP cells are poorly tumorigenic and metastatic
[30]. In the clinical samples, the expression levels of miR-
23a and miR-23b were significantly lower compared with
prostate tissue derived from BPH cases, a finding which was
consistent with our in vitro cell line data. Several other studies
have also shown decreased levels of miR-23a and miR-23b in
prostate cancer samples [31, 32]. Nonetheless, while our clin-
ical samples were similar in terms of pathology, some samples
demonstrated an increased expression of the miRNAs. The
heterogeneity in miR-23b levels in prostate cancer tissues
has been previously reported. For example, Majid et al. [33]
and Sun et al. [34] reported enhanced levels of miR-23b in
some cancer tissues. The increased expression of miR-23a and
miR-23b in some clinical samples may be a consequence of
individual genetic polymorphisms. Interestingly, it has been
recently reported that in vivo intratumoral delivery of miR-
23b mature sequences in a murine model of prostate cancer
can considerably reduce tumor mass in animals, an effect at-
tributed to the suppression of proto-oncogenic pathways in
neoplastic cells [33].
While in this work we have focused on MAPK and JAK/
STAT pathway genes and their potential targeting by
miRNAs in the context of prostate cancer, soluble growth
factors and cytokines that activate these pathways could be
equally important in disease pathogenesis. IL-6 is one of the
cytokines which signals through the JAK/STAT pathway,
and several reports have also pointed to the role of IL-6 in
promoting prostate cancer [35, 36]. The expression of IL-6
and its receptor, IL-6R, is upregulated in prostate cancer
cells, and suppressing IL-6 levels in prostate cancer cell
lines using small interfering RNAs decreases cell prolifera-
tion [37]. Considering the importance of IL-6R in prostate
cancer, we selected this gene for analysis, and our results
show that overexpression of both mir-23a and mir-23b
Fig. 5 Expression of miR-23,
miR-23b, and IL-6R in each
clinical sample. P values less than
0.05, 0.01, and 0.001 are marked
with an asterisk (*), two asterisks
(**), and three asterisks (***),
respectively
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decreased IL-6R expression in LNCAP and PC3 cell lines.
In addition, IL-6R in all clinical samples was upregulated
unlike mir-23a and mir-23b that were downregulated. Inter-
estingly, IL-6R is also a confirmed target of miR-23a [38].
The role of IL-6 signaling in the pathogenesis of prostate
cancer, together with the inhibitory effect of miR-23a on IL-
6 receptor, gives more weight to miR-23a as a candidate for
prostate cancer therapy.
Conclusion
miRNA-based therapy is an attractive strategy for therapeutic
gene silencing. miRNAs can affect cellular processes through
controlling the gene expressionmachinery. Using a miRNA as
therapeutic target may influence several cellular pathways at
once and exert a more robust effect compared with the
targeting of individual protein-coding genes. That said, this
might also lead to nonspecific effects which need to be eval-
uated prior to clinical use of miRNAs. In this study, we pro-
vided some evidence showing that miR-23a and miR-23b can
target IL-6R which signals through the JAK/STAT pathway,
and in turn, this pathway controls cell proliferation, develop-
ment, and survival in the context of cancer. Moreover, we
confirmed that these miRNAs are downregulated in prostate
cancer cells. Altogether, our results represent the possibility of
using miR-23a and miR-23b as therapeutic targets in prostate
cancer.
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